Coronary interventions in Europe 1992. The Working Group on Coronary Circulation of the European Society of

C Röthlisberger1, B Meier

  • 1Cardiology, University Hospital, Bern, Switzerland.

Insights

This survey reveals wide variations in coronary angiography and percutaneous transluminal coronary angioplasty (PTCA) rates across European countries. PTCA is a well-accepted treatment for coronary artery disease, frequently performed more often than coronary artery bypass grafting (CABG).

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Public Health

Background:

  • Coronary interventions are influenced by diverse factors including traditional, cultural, socioeconomic, and personal aspects.
  • Data on coronary intervention practices across European Society of Cardiology member countries were previously limited.

Purpose of the Study:

  • To collect and analyze data on coronary interventions across member countries of the European Society of Cardiology.
  • To assess the incidence and trends of coronary angiography and percutaneous transluminal coronary angioplasty (PTCA).

Main Methods:

  • Survey distributed to national members of the European Society of Cardiology.
  • Data collection on coronary angiograms, percutaneous transluminal coronary angioplasty (PTCA), stent implantation, and coronary artery bypass grafting (CABG).
  • Exclusion of data from 12 countries due to missing or incomplete information.

Main Results:

  • A total of 683,888 coronary angiograms were reported, with significant variations in incidence per million inhabitants across countries.
  • 147,729 percutaneous transluminal coronary angioplasties (PTCA) were performed, accounting for 19% of angiograms, with Germany reporting the highest incidence.
  • Stent implantation was the most common additional procedure in PTCA (2.7%), while other new devices were rarely used; PTCA was performed more frequently than CABG (ratio 2.3).

Conclusions:

  • Percutaneous transluminal coronary angioplasty (PTCA) is a well-accepted treatment for coronary artery disease.
  • Significant disparities exist in the rates of coronary angiography and PTCA per million inhabitants across Europe.
  • Stent implantation is common, but the application of other novel interventional devices remains limited.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...